Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

fibrosarcoma

  • Open Access
    Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma
    SEI MORINAGA, QINGHONG HAN, KOHEI MIZUTA, BYUNG MO KANG, MOTOKAZU SATO, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA and ROBERT M. HOFFMAN
    Anticancer Research September 2024, 44 (9) 3777-3783; DOI: https://doi.org/10.21873/anticanres.17202
  • Open Access
    Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem
    SEI MORINAGA, QINGHONG HAN, KOHEI MIZUTA, BYUNG M KANG, MOTOKAZU SATO, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA and ROBERT M. HOFFMAN
    Anticancer Research September 2024, 44 (9) 3785-3791; DOI: https://doi.org/10.21873/anticanres.17203
  • Open Access
    Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma
    SEI MORINAGA, QINGHONG HAN, KOHEI MIZUTA, BYUNG MO KANG, MOTOKAZU SATO, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA and ROBERT M. HOFFMAN
    Anticancer Research August 2024, 44 (8) 3261-3268; DOI: https://doi.org/10.21873/anticanres.17144
  • Open Access
    DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts
    SEI MORINAGA, QINGHONG HAN, YUTARO KUBOTA, KOHEI MIZUTA, BYUNG MO KANG, MOTOKAZU SATO, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA and ROBERT M. HOFFMAN
    Anticancer Research June 2024, 44 (6) 2359-2367; DOI: https://doi.org/10.21873/anticanres.17043
  • Open Access
    Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts
    SEI MORINAGA, QINGHONG HAN, YUTARO KUBOTA, KOHEI MIZUTA, BYUNG MO KANG, MOTOKAZU SATO, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA and ROBERT M. HOFFMAN
    Anticancer Research March 2024, 44 (3) 921-928; DOI: https://doi.org/10.21873/anticanres.16886
  • You have access
    A Standardized Extract of Cultured Lentinula edodes mycelia Up-regulates COX-2 in Inflammation-related Malignant Progressive Fibrosarcoma Cell Clone QRsP-11
    TAKAO KITAGAWA, SHAJEDUL ISLAM, BYRON BARON, KAZUHIRO TOKUDA, DURGA PAUDEL, TOHRU OHTA, KOJI NAKAGAWA, MASANOBU KOBAYASHI, FUTOSHI OKADA and YASUHIRO KURAMITSU
    Anticancer Research March 2023, 43 (3) 1239-1244; DOI: https://doi.org/10.21873/anticanres.16270
  • You have access
    Preoperative Risk Factors for Fibrosarcomatous Transformation in Dermatofibrosarcoma Protuberans
    KATHERINE E. MALLETT, SARAH ALMUBARAK, RYAN M. CLAXTON, PETER C. FERGUSON, ANTHONY M. GRIFFIN, PETER S. ROSE, JAY S. WUNDER, KIM TSOI and MATTHEW T. HOUDEK
    Anticancer Research January 2022, 42 (1) 105-108; DOI: https://doi.org/10.21873/anticanres.15463
  • You have access
    Clinicopathological Characteristics of Mitotically-active Cellular Fibroma of the Ovary: A Single-institutional Experience
    JI-YE KIM, KIYONG NA and HYUN-SOO KIM
    Anticancer Research May 2017, 37 (5) 2557-2564;
  • You have access
    Resveratrol Induces Apoptosis and Alters Gene Expression in Human Fibrosarcoma Cells
    KAMRAN HARATI, PAWEL SLODNIK, ANSGAR MICHAEL CHROMIK, OLE GOERTZ, TOBIAS HIRSCH, NIKOLAI KAPALSCHINSKI, LUDGER KLEIN-HITPASS, JONAS KOLBENSCHLAG, WALDEMAR UHL, MARCUS LEHNHARDT and ADRIEN DAIGELER
    Anticancer Research February 2015, 35 (2) 767-774;
  • You have access
    Imaging Nuclear - Cytoplasm Dynamics of Cancer Cells in the Intravascular Niche of Live Mice
    ATSUSHI SUETSUGU, PING JIANG, HISATAKA MORIWAKI, SHIGETOYO SAJI, MICHAEL BOUVET and ROBERT M. HOFFMAN
    Anticancer Research October 2013, 33 (10) 4229-4236;

Pages

  • Next
  • 1
  • 2
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire